If everything goes well with the development of Pellepharm’s treatment for Gorlin syndrome, patidegib, the company will launch the drug in 2022. With this time frame in mind, the company’s Danish partner, Leo Pharma, has now assembled a team to help the small, San Francisco-based company with its launch plans.
This is despite the fact that Leo Pharma has not yet decided whether to use the option agreement it has with Pellepharm to buy the company.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Long wait for IVDR implementation is over, putting an end to pandemic "wild west"
After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26.
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
US to start using Bavarian vaccine stockpile
In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease.
Bavarian Nordic upgrades guidance following vaccine contract
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
IRT Manager, Clinical Drug Supply 
Senior Chemical Safety Advisor 
Industrial Designer- Design Engineer 
Director of Toxicology 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
2 Sales Representatives and Product Specialists 
Clinical Project Manager 
Clinical Trial Manager for development of in vitro diagnostics 
Laboratory technician for process development and clinical manufacturing 
Biomarker Operations Lead 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Communications Consultant 
Senior Project Manager (GMP - Life Science) 
Nordic Medical Affairs Manager 
Account Manager